By otakuyassine3@gmail.com 
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report)’s share price fell 5.6% during trading on Wednesday . The company traded as low as $7.04 and last traded at $7.02. 8,745,283 shares changed hands during mid-day trading, a decline of 48% from the average session volume of 16,670,846 shares. The stock had previously closed at $7.43.
Analysts Set New Price Targets
A number of research firms have recently commented on RXRX. KeyCorp dropped their price objective on Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Wednesday, January 8th. Needham & Company LLC reiterated a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Wednesday, December 11th.
Check Out Our Latest Report on Recursion Pharmaceuticals
Recursion Pharmaceuticals Stock Down 5.9 %
The company has a debt-to-equity ratio of 0.04, a current ratio of 4.35 and a quick ratio of 4.35. The stock has a market capitalization of $2.83 billion, a P/E ratio of -4.73 and a beta of 0.85. The firm has a 50 day moving average of $7.00 and a 200-day moving average of $6.94.
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $26.08 million during the quarter, compared to the consensus estimate of $12.62 million. During the same quarter in the prior year, the company posted ($0.43) earnings per share. The company’s revenue for the quarter was up 147.6% on a year-over-year basis. On average, equities research analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.
Insider Activity
In other news, Director Blake Borgeson sold 11,447 shares of the business’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $7.64, for a total value of $87,455.08. Following the transaction, the director now directly owns 7,066,113 shares of the company’s stock, valued at $53,985,103.32. The trade was a 0.16 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael Secora sold 15,000 shares of the business’s stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the transaction, the chief financial officer now directly owns 1,499,631 shares in the company, valued at $11,487,173.46. The trade was a 0.99 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 15.75% of the company’s stock.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently modified their holdings of RXRX. Hsbc Holdings PLC boosted its holdings in shares of Recursion Pharmaceuticals by 26.0% in the 2nd quarter. Hsbc Holdings PLC now owns 27,972 shares of the company’s stock worth $206,000 after acquiring an additional 5,764 shares in the last quarter. Xponance Inc. acquired a new position in Recursion Pharmaceuticals during the 2nd quarter worth $98,000. The Manufacturers Life Insurance Company lifted its holdings in Recursion Pharmaceuticals by 32.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 111,613 shares of the company’s stock worth $837,000 after buying an additional 27,440 shares in the last quarter. Algert Global LLC acquired a new position in Recursion Pharmaceuticals during the 2nd quarter worth $129,000. Finally, SG Americas Securities LLC lifted its holdings in Recursion Pharmaceuticals by 249.0% during the 3rd quarter. SG Americas Securities LLC now owns 89,325 shares of the company’s stock worth $589,000 after buying an additional 63,727 shares in the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
See Also
Receive News & Ratings for Recursion Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.